Phloroglucinol inhibits the bioactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Kwon, Yi Hong ^b   Jung, Seok Yun ^a   Kim, Jae Won ^b   Lee, Sang Hun ^a   Lee, Jun Hee ^a   Lee, Boo Yong ^b   Kwon, Sang Mo ^a  

^a Pusan National University   (South Korea)

^b CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PHLOROGLUCINOL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; COLLAGEN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; LAMININ; MATRIGEL; PROTEOGLYCAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; UMBILICAL CORD BLOOD; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); ORAL DRUG ADMINISTRATION; PATHOLOGY; STEM CELL; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ECKLONIA CAVA; MUS;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDICATORS AND REAGENTS; LAMININ; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PHLOROGLUCINOL; PROTEOGLYCANS; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859514068     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033618     Document Type: Article

References (41)

1. Kim MM, Kim SK, (2010) Effect of phloroglucinol on oxidative stress and inflammation. Food Chem Toxicol 48: 2925-2933.
2. Kang KA, Lee KH, Chae S, Zhang R, Jung MS, et al. (2006) Cytoprotective effect of phloroglucinol on oxidative stress induced cell damage via catalase activation. J Cell Biochem 97: 609-620.
3. Singh IP, Sidana J, Bansal P, Foley WJ, (2009) Phloroglucinol compounds of therapeutic interest: global patent and technology status. Expert Opin Ther Pat 19: 847-866.
4. Gupta P, Kumar R, Garg P, Singh IP, (2010) Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase. Bioorg Med Chem Lett 20: 4427-4431.
5. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC, (2006) Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 3: 682-692.
6. Cragg GM, Newman DJ, (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79.
7. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, et al. (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28: 858-864.
8. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, et al. (2008) Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7: 1789-1796.
9. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221-228.
10. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, et al. (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972.
11. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, et al. (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434-438.
12. Oh HK, Ha JM, O E, Lee BH, Lee SK, et al. (2007) Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res 67: 4851-4859.
13. Kwon SM, Suzuki T, Kawamoto A, Ii M, Eguchi M, et al. (2009) Pivotal role of lnk adaptor protein in endothelial progenitor cell biology for vascular regeneration. Circ Res 104: 969-977.
14. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
15. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, et al. (2008) VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99: 622-631.
16. Zhu W, Xu W, Jiang R, Qian H, Chen M, et al. (2006) Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80: 267-274.
17. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
18. Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, et al. (2011) Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer 128: 1505-1508.
19. Fang S, Salven P, (2011) Stem cells in tumor angiogenesis. J Mol Cell Cardiol 50: 290-295.
20. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, et al. (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796: 33-40.
21. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
22. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, et al. (2006) Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44: 836-843.
23. Dome B, Timar J, Dobos J, Meszaros L, Raso E, et al. (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66: 7341-7347.
24. Li Y, Qian ZJ, Ryu B, Lee SH, Kim MM, et al. (2009) Chemical components and its antioxidant properties in vitro: an edible marine brown alga, Ecklonia cava. Bioorg Med Chem 17: 1963-1973.
25. Schempp CM, Kiss J, Kirkin V, Averbeck M, Simon-Haarhaus B, et al. (2005) Hyperforin acts as an angiogenesis inhibitor. Planta Med 71: 999-1004.
26. Rothley M, Schmid A, Thiele W, Schacht V, Plaumann D, et al. (2009) Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125: 34-42.
27. Dona M, Dell'Aica I, Pezzato E, Sartor L, Calabrese F, et al. (2004) Hyperforin inhibits cancer invasion and metastasis. Cancer Res 64: 6225-6232.
28. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, et al. (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189.
29. Hicklin DJ, Ellis LM, (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
30. Tonra JR, Hicklin DJ, (2007) Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 36: 3-23.
31. Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, et al. (2009) Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 86: 204-213.
32. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, et al. (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81-86; discussion 86.
33. Porta C, Paglino C, Imarisio I, Bonomi L, (2007) Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7: 127-134.
34. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
35. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
36. Deryugina EI, Quigley JP, (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34.
37. Liotta LA, Steeg PS, Stetler-Stevenson WG, (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
38. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, et al. (1996) Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56: 2815-2822.
39. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104: 2752-2760.
40. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
41. Jung MH, Lee SH, Ahn EM, Lee YM, (2009) Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30: 655-661.